L3VLUP
ProSign in

CGEN in the 13F filings

Compugen LTD · CUSIP M25722105

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q2 2025Q1 2025Q3 2024Q2 2024Q1 2024Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Quarter end
31 Dec 2022
the date the book describes
Filed
14 Feb 2023
latest of these filings; the earliest 24 Jan 2023
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2022 and Q4 2022; 1 listed it in both
Shares listed
2,410,414
combined, among listed positions
Reported value
$1.7m
combined, at the quarter end

Managers listing CGEN in Q4 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
ARK Investment Management LLC2,410,414$1.7munder 0.1%Added+1,252,93024 Jan 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2022 to Q4 2022, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q4 2022 to 1 in Q2 2026

Tracked managers listing it, at least.

0246201720182019202020212022202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
CGEN by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20161$1.1mn.a.n.a.
Q1 20171$1.2mn.a.n.a.
Q2 20171$2.1mn.a.n.a.
Q3 20171$4.4mn.a.n.a.
Q4 20171$5.6mn.a.n.a.
Q1 20181$18mn.a.n.a.
Q2 20181$18mn.a.n.a.
Q3 20181$27mn.a.n.a.
Q4 20181$15mn.a.n.a.
Q1 20191$34mn.a.n.a.
Q2 20191$33mn.a.n.a.
Q3 20191$37mn.a.n.a.
Q4 20191$53mn.a.n.a.
Q1 20202$77mn.a.n.a.
Q2 20203$221mn.a.n.a.
Q3 20203$301mn.a.n.a.
Q4 20205$222mn.a.n.a.
Q1 20215$137mn.a.n.a.
Q2 20213$107mn.a.n.a.
Q3 20213$64mn.a.n.a.
Q4 20213$44mn.a.n.a.
Q1 20222$36mn.a.n.a.
Q2 20222$21mn.a.n.a.
Q3 20222$2.1mn.a.n.a.
Q4 20221$1.7mn.a.n.a.
Q1 20241$2.7m10
Q2 20241$1.9m10
Q3 20241$2.0m10
Q1 20251$1.3m10
Q2 20251$1.8m10
Q1 20261$2.2m63
Q2 20261$1.7m84

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

CGEN and GILD →CGEN and AMGN →CGEN and ARGX →Choose a stock to compare with CGEN →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own CGEN, latest filings →Back to the 13F Explorer →